{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:39Z","timestamp":1792831059625,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001738","name":"Israel Ministry of Innovation Science & Technology","doi-asserted-by":"publisher","award":["0008062"],"award-info":[{"award-number":["0008062"]}],"id":[{"id":"10.13039\/501100001738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110607","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:29:19Z","timestamp":1790922559000},"page":"110607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC"],"prefix":"10.1016","volume":"183","author":[{"given":"Pousali","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Panja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Pirthwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bat Chen R.","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-2751","authenticated-orcid":false,"given":"Dror","family":"Tobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-8707","authenticated-orcid":false,"given":"Gary","family":"Gellerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bioorg.2026.110607_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung Cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10299","key":"10.1016\/j.bioorg.2026.110607_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung Cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.vacun.2023.12.003","article-title":"A review on non-small cell lung Cancer","volume":"25","author":"Verma","year":"2024","journal-title":"Vacunas"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110607_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9090120","article-title":"Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer","volume":"9","author":"Verma","year":"2017","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110607_bb0025","first-page":"437","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110607_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s44276-024-00064-8","article-title":"New light on chemotherapy toxicity and its prevention","volume":"2","author":"Juthani","year":"2024","journal-title":"BJC Rep."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110607_bb0035","article-title":"The incidence and severity of patient-reported side effects of chemotherapy in routine clinical care: a prospective observational study","volume":"15","author":"Katta","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110607_bb0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung Cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110607_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117794","article-title":"Synthesis and anticancer properties of novel Dolastatin 10 Analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminus","volume":"109","author":"Panja","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110607_bb0055","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.2147\/CMAR.S186042","article-title":"The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer","volume":"11","author":"Battaglin","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"Spec Feature","key":"10.1016\/j.bioorg.2026.110607_bb0060","first-page":"119","article-title":"Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non\u2013small-cell lung cancer","volume":"9","author":"Fala","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.bioorg.2026.110607_bb0065","doi-asserted-by":"crossref","unstructured":"Genova, C.; Hirsch, F. R. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco. Targets Ther. 2016, 9, 5427\u20135437. doi:https:\/\/doi.org\/10.2147\/OTT.S114039.","DOI":"10.2147\/OTT.S114039"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1535-7163.MCT-17-0575","article-title":"Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance","volume":"17","author":"Bagchi","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide\u2013drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110607_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4020011","article-title":"Recent innovations in peptide based targeted drug delivery to cancer cells","volume":"4","author":"Gilad","year":"2016","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110607_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31071180","article-title":"Antibody\u2013drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives","volume":"31","author":"Wu","year":"2026","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110607_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70040","article-title":"Peptide-drug conjugates: a new hope for cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.bioorg.2026.110607_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: a new paradigm for targeted Cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110607_bb0105","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110607_bb0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of Gastroenteropancreatic neuroendocrine Tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/cr960065d","article-title":"Phage display","volume":"97","author":"Smith","year":"1997","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110607_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071505","article-title":"Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery","volume":"14","author":"Furman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110607_bb0125","doi-asserted-by":"crossref","unstructured":"RNA-peptide fusions for the in vitro selection of peptides and proteins | PNAS. https:\/\/doi.org\/10.1073\/pnas.94.23.12297 (accessed 2026-06-26).","DOI":"10.1073\/pnas.94.23.12297"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110607_bb0130","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1073\/pnas.81.13.3998","article-title":"Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid","volume":"81","author":"Geysen","year":"1984","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.110607_bb0135","doi-asserted-by":"crossref","unstructured":"Virtual screening of peptide libraries: the search for peptide-based therapeutics using computational tools 2026. https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1798 (accessed 2026-06-18).","DOI":"10.3390\/ijms25031798"},{"key":"10.1016\/j.bioorg.2026.110607_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114766","article-title":"High throughput virtual screening (HTVS) of peptide library: technological advancement in ligand discovery","volume":"243","author":"Tripathi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110607_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.aspetd.2026.100024","article-title":"Advances in computer-aided drug design: from molecular docking to artificial intelligence-driven therapeutic discovery","volume":"2","author":"Fahim","year":"2026","journal-title":"ASPET Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110607_bb0155","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s13738-016-0898-7","article-title":"An in silico approach to design peptide mimetics based on docking and molecular dynamics simulation of EGFR\u2013Matuzumab complex","volume":"13","author":"Ebrahimi","year":"2016","journal-title":"J. Iran. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110607_bb0160","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41598-018-37201-6","article-title":"A rational approach for creating peptides mimicking antibody binding","volume":"9","author":"Sachdeva","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110607_bb0165","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1021\/acs.molpharmaceut.5c01774","article-title":"EGFR-targeted and MMP-activated membranolytic peptides kill Cancer cells specifically in vitro and reduce tumor growth in vivo","volume":"23","author":"Pramanik","year":"2026","journal-title":"Mol. Pharm."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110607_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249535","article-title":"EGFR-binding peptides: from computational design towards tumor-targeting of adeno-associated virus capsids","volume":"21","author":"Feiner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110607_bb0175","doi-asserted-by":"crossref","first-page":"19620","DOI":"10.18632\/oncotarget.7746","article-title":"The afatinib resistance of in vivo generated H1975 lung Cancer cell clones is mediated by SRC\/ERBB3\/c-KIT\/c-MET compensatory survival Signaling","volume":"7","author":"Booth","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110607_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110607_bb0185","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFRL858R\/T790M and EGFRL858R\/T790M\/C797S resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110607_bb0190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.phrs.2017.01.003","article-title":"Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment","volume":"117","author":"Passaro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110607_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2026.118674","article-title":"Peptide\u2013drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo","volume":"138","author":"Panja","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110607_bb0200","author":"Bank"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110607_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17070866","article-title":"Applying unbiased, functional criteria allows selection of novel cyclic peptides for effective targeted drug delivery to malignant prostate cancer cells","volume":"17","author":"Cohen","year":"2025","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110607_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139652","article-title":"Cell-penetrating peptides selectively cross the blood-brain barrier in vivo","volume":"10","author":"Stalmans","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110607_bb0215","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.7150\/thno.24378","article-title":"Site-specific stabilization of Minigastrin Analogs against enzymatic degradation for enhanced Cholecystokinin-2 receptor targeting","volume":"8","author":"Klingler","year":"2018","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110607_bb0220","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.3892\/ol.2016.5373","article-title":"HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib","volume":"12","author":"Xu","year":"2016","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110607_bb0225","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.1038\/s41467-022-34627-5","article-title":"A fluorogenic probe for predicting treatment response in non-small cell lung Cancer with EGFR-activating mutations","volume":"13","author":"Deng","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110607_bb0230","first-page":"5201","article-title":"Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung Cancer cells via the extracellular signal-regulated kinase\/microRNA 200a Signaling pathway","volume":"15","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/BJ20060816","article-title":"EGFR-mediated expression of Aquaporin-3 is involved in human skin fibroblast migration","volume":"400","author":"Cao","year":"2006","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110607_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121613","article-title":"Novel cyclic peptide\u2013drug conjugate P6-SN38 toward targeted treatment of EGFR overexpressed non-small cell lung cancer","volume":"16","author":"Bazylevich","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110607_bb0245","doi-asserted-by":"crossref","unstructured":"Ayali, S.; Panja, A.; Mitra, P.; Gupta, Y. D.; Tobi, D.; Bazylevich, A.; Brenner, B.; Cohen, Z.; Ayale, A. R.; Nesher, E.; Gellerman, G.; Lubin, B. C. R. Toward targeting the untargetable: a non-canonical EGFR-peptide\u2013drug conjugate achieves potent antitumor activity in KRAS-mutant CRC. J. Control. Release 2026, 114993. doi:https:\/\/doi.org\/10.1016\/j.jconrel.2026.114993.","DOI":"10.1016\/j.jconrel.2026.114993"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110607_bb0250","first-page":"85","article-title":"Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal Cancer: a systematic review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110607_bb0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110607_bb0260","author":"Bank"},{"key":"10.1016\/j.bioorg.2026.110607_bb0270","doi-asserted-by":"crossref","unstructured":"Desmond | Schr\u00f6dinger Life Science. Schr\u00f6dinger. https:\/\/www.schrodinger.com\/platform\/products\/desmond\/ (accessed 2026-04-01).","DOI":"10.33140\/OAJAST.04.02.06"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110607_bb0280","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110607_bb0285","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1063\/1.463940","article-title":"Nos\u00e9\u2013Hoover chains: the canonical ensemble via continuous dynamics","volume":"97","author":"Martyna","year":"1992","journal-title":"J. Chem. Phys."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110607_bb0290","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110607_bb0295","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.bioorg.2026.110607_bb0310","series-title":"Leading DNA & RNA amplification reagent provider","year":"2026"},{"key":"10.1016\/j.bioorg.2026.110607_bb0320","series-title":"XTT Cell Viability Assay Kit","year":"2026"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:07:36Z","timestamp":1792829256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"alternative-id":["S0045206826011430"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110607","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110607"}}